Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 4Neoplasms 3Lymphoma, Non-Hodgkin 3Advanced Cancer 3Uveal Melanoma 2Recurrence 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Hodgkin Disease 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Various Advanced Cancer 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Site 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × relatlimab × Clear all
NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

University of Miami

Phase 2 Completed
27 enrolled 9 charts
Dermatologic

Uveal Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

M.D. Anderson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡